HK1118577A1 - Rnai expression constructs rnai - Google Patents

Rnai expression constructs rnai

Info

Publication number
HK1118577A1
HK1118577A1 HK08112495.7A HK08112495A HK1118577A1 HK 1118577 A1 HK1118577 A1 HK 1118577A1 HK 08112495 A HK08112495 A HK 08112495A HK 1118577 A1 HK1118577 A1 HK 1118577A1
Authority
HK
Hong Kong
Prior art keywords
rnai
expression constructs
organs
genes
disorders
Prior art date
Application number
HK08112495.7A
Other languages
English (en)
Inventor
Petrus W Roelvink
David A Suhy
Alexander A Kolykhalov
Linda Couto
Original Assignee
Benitec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Benitec Inc filed Critical Benitec Inc
Publication of HK1118577A1 publication Critical patent/HK1118577A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/51—Physical structure in polymeric form, e.g. multimers, concatemers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK08112495.7A 2005-02-03 2008-11-14 Rnai expression constructs rnai HK1118577A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64964105P 2005-02-03 2005-02-03
US65358005P 2005-02-15 2005-02-15
PCT/US2006/004003 WO2006084209A2 (fr) 2005-02-03 2006-02-03 Produits de synthese d'expression d'arni

Publications (1)

Publication Number Publication Date
HK1118577A1 true HK1118577A1 (en) 2009-02-13

Family

ID=36603389

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08112495.7A HK1118577A1 (en) 2005-02-03 2008-11-14 Rnai expression constructs rnai

Country Status (10)

Country Link
US (4) US8076471B2 (fr)
EP (2) EP1844145A2 (fr)
CN (1) CN101180394B (fr)
AU (1) AU2006210443B2 (fr)
CA (1) CA2596711C (fr)
DK (1) DK2172549T3 (fr)
HK (1) HK1118577A1 (fr)
IL (1) IL185315A0 (fr)
NZ (1) NZ560936A (fr)
WO (1) WO2006084209A2 (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ560936A (en) 2005-02-03 2010-04-30 Benitec Inc RNAI expression constructs
GB0708662D0 (en) * 2007-05-04 2007-06-13 Galapagos Nv shRNA sequences
EP2173900A4 (fr) * 2007-06-22 2010-12-29 Alnylam Pharmaceuticals Inc Molécules effectrices d'arn double brin d'hépatite c, constructions d'expression, compositions, et procédés d'utilisation
US9217155B2 (en) 2008-05-28 2015-12-22 University Of Massachusetts Isolation of novel AAV'S and uses thereof
US8435790B2 (en) * 2008-07-25 2013-05-07 The Regents Of The University Of California Methods of modulating lipid concentrations in eukaryotic cells
US8734809B2 (en) 2009-05-28 2014-05-27 University Of Massachusetts AAV's and uses thereof
US9200276B2 (en) 2009-06-01 2015-12-01 Halo-Bio Rnai Therapeutics, Inc. Polynucleotides for multivalent RNA interference, compositions and methods of use thereof
AU2011223820B2 (en) 2010-03-01 2016-01-14 The Children's Hospital Of Philadelphia Nucleic acids for targeting multiple regions of the HCV genome
ES2631458T3 (es) 2010-03-04 2017-08-31 Interna Technologies B.V. Molécula de ARNmi definida por su fuente y sus usos terapéuticos en el cáncer asociado a la EMT
CA2833912C (fr) 2010-04-23 2021-09-21 University Of Massachusetts Traitement a base d'aav pour des troubles lies au cholesterol
US9546369B2 (en) 2010-04-23 2017-01-17 University Of Massachusetts Multicistronic expression constructs
ES2698203T3 (es) 2010-04-23 2019-02-01 Univ Massachusetts Vectores de AAV que se dirigen al SNC y métodos de uso de los mismos
NZ704322A (en) 2010-07-06 2016-07-29 Interna Technologies Bv Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
CA2853613C (fr) 2010-10-28 2020-03-24 Benitec Biopharma Limited Traitement d'une infection par le vhb
EP2474617A1 (fr) 2011-01-11 2012-07-11 InteRNA Technologies BV MIR pour traiter une nouvelle angiogenèse
US9226936B2 (en) 2011-10-28 2016-01-05 The Wistar of Anatomy and Biology Methods and compositions for enhancing the therapeutic effect of anti-tumor T cells
US10238755B2 (en) 2011-11-30 2019-03-26 The Wistar Institute Of Anatomy And Biology Methods and compositions for regulation of cell aging, carcinogenesis and reprogramming
EP2794881B1 (fr) 2011-12-22 2018-06-27 InteRNA Technologies B.V. Miarn pour le traitement du cancer de la tête et du cou
EP2917348A1 (fr) 2012-11-06 2015-09-16 InteRNA Technologies B.V. Association médicamenteuse utilisable en vue du traitement de maladies ou d'affections associées au mélanome ou à l'activation de la voie de signalisation braf
EP2943571A4 (fr) * 2013-01-08 2016-11-30 Benitec Biopharma Ltd Traitement de la dégénérescence maculaire liée à l'âge
KR20170045347A (ko) 2014-09-07 2017-04-26 셀렉타 바이오사이언시즈, 인크. 엑손 스키핑 항-바이러스 전달 벡터 면역 반응을 약화시키기 위한 방법 및 조성물
ES2870607T3 (es) 2014-10-02 2021-10-27 Wistar Inst Métodos y composiciones para tratar cáncer
WO2016065001A1 (fr) 2014-10-21 2016-04-28 University Of Massachusetts Variants de vaa recombinants et leurs utilisations
CN112410338A (zh) 2014-11-14 2021-02-26 沃雅戈治疗公司 调节性多核苷酸
RU2020108189A (ru) 2014-11-14 2020-03-11 Вояджер Терапьютикс, Инк. Композиции и способы лечения бокового амиотрофического склероза (als)
JP2018525037A (ja) 2015-08-24 2018-09-06 ハロー−バイオ・アールエヌエーアイ・セラピューティックス、インコーポレイテッド 遺伝子発現の調節のためのポリヌクレオチドナノ粒子及びその使用
EP3356531A4 (fr) * 2015-10-01 2019-05-29 Apse Llc Procédés et compositions comprenant des noeuds apse
EP3416668A4 (fr) 2016-02-18 2020-02-19 The Wistar Institute Of Anatomy And Biology Méthodes et compositions pour le traitement du mélanome
CA3024449A1 (fr) 2016-05-18 2017-11-23 Voyager Therapeutics, Inc. Compositions et methodes de traitement de la maladie de huntington
KR20240056729A (ko) 2016-05-18 2024-04-30 보이저 테라퓨틱스, 인크. 조절성 폴리뉴클레오티드
AU2017341849B2 (en) 2016-10-13 2024-03-21 University Of Massachusetts AAV capsid designs
CA3061652A1 (fr) 2017-05-05 2018-11-08 Voyager Therapeutics, Inc. Compositions et methodes de traitement de la sclerose laterale amyotrophique (sla)
MX2019013172A (es) 2017-05-05 2020-09-07 Voyager Therapeutics Inc Composiciones y metodos para tratar la enfermedad de huntington.
US20190142974A1 (en) 2017-10-13 2019-05-16 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
US20200237799A1 (en) 2017-10-16 2020-07-30 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
TWI804518B (zh) 2017-10-16 2023-06-11 美商航海家醫療公司 肌萎縮性脊髓側索硬化症(als)之治療
AU2018358016A1 (en) 2017-11-03 2020-05-07 Interna Technologies B.V. MiRNA molecule, equivalent, antagomir, or source thereof for treating and/or diagnosing a condition and/or a disease associated with neuronal deficiency or for neuronal (re)generation
AU2020284555A1 (en) 2019-05-28 2021-12-23 Selecta Biosciences, Inc. Methods and compositions for attenuated anti-viral transfer vector immune response
CN111454955B (zh) * 2020-04-27 2023-05-12 广西壮族自治区林业科学研究院 源于尾叶桉CAD基因序列的RNAi片段及其应用
WO2023064367A1 (fr) 2021-10-12 2023-04-20 Selecta Biosciences, Inc. Méthodes et compositions permettant d'atténuer les réponses anti-igm de vecteur de transfert viral
US20230357437A1 (en) 2022-03-09 2023-11-09 Selecta Biosciences, Inc. Immunosuppressants in combination with anti-igm agents and related dosing
GB202208347D0 (en) 2022-06-07 2022-07-20 Univ Court Univ Of Glasgow Targets for cancer therapy

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6218181B1 (en) 1998-03-18 2001-04-17 The Salk Institute For Biological Studies Retroviral packaging cell line
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
US6509323B1 (en) 1998-07-01 2003-01-21 California Institute Of Technology Linear cyclodextrin copolymers
EP1192455B1 (fr) * 1999-06-08 2014-07-02 Broadley Technologies Corporation Electrode de réference avec jonction d'écoulement liquide microfluidique
US6487450B1 (en) * 2000-02-24 2002-11-26 Cedars-Sinai Medical Center System and method for preventing Sudden Cardiac Death by nerve sprouting from right stellate ganglion
IL151781A0 (en) 2000-03-16 2003-04-10 Genetica Inc Methods and compositions for rna interference
US20020162128A1 (en) * 2000-04-19 2002-10-31 Akemichi Baba Non-human animal deficient in function of pituitary adenylate cyclase-activating polypeptide gene
JP4344858B2 (ja) 2001-09-13 2009-10-14 カリフォルニア インスティチュート オブ テクノロジー 細胞内で抗ウイルス性小ｒｎａ分子を発現させる方法
US6758254B2 (en) * 2001-10-16 2004-07-06 Nautilus Systems, Inc. Method and apparatus for removing and applying adhesive components
CA2457528C (fr) * 2002-02-20 2011-07-12 Sirna Therapeutics, Inc. Inhibition a mediation par interference arn de l'expression du gene du virus de l'hepatite c (vhc) au moyen d'acide nucleique interferent court (sina)
DE10212892A1 (de) * 2002-03-20 2003-10-09 Basf Plant Science Gmbh Konstrukte und Verfahren zur Regulation der Genexpression
US20040053876A1 (en) * 2002-03-26 2004-03-18 The Regents Of The University Of Michigan siRNAs and uses therof
DE60326961D1 (de) * 2002-07-26 2009-05-14 Novartis Vaccines & Diagnostic Modifizierte kleine irns moleküle und methoden zu deren anwendung
RU2005106999A (ru) 2002-08-29 2005-08-27 Дзе Борд Оф Трастиз Оф Дзе Лелэнд Стэнфорд Джуниор Юниверсити (Us) Кольцевые векторы нуклеиновой кислоты и способы их создания и использования
KR20050084607A (ko) * 2002-09-28 2005-08-26 매사추세츠 인스티튜트 오브 테크놀로지 인플루엔자 치료제
WO2004078974A1 (fr) 2003-01-24 2004-09-16 Tokyo Metropolitan Organization For Medical Research Oligoribonucleotide ou acide nucleique peptidique inhibant la fonction du virus de l'hepatite c
WO2004085623A2 (fr) 2003-03-24 2004-10-07 University Of Pittsburgh Of The Commonwealth System Of Higher Education Vecteur d'expression de synthese compact comprenant des molecules d'adn double brin et methodes d'utilisation de ce vecteur
WO2004106517A1 (fr) * 2003-06-03 2004-12-09 Benitec Australia Limited Acide nucleique double brin
CN1276086C (zh) * 2003-08-13 2006-09-20 复旦大学 一类双链rna分子及其在制备抑制乙型肝炎病毒复制药物中的应用
US20050087926A1 (en) * 2003-09-26 2005-04-28 Aruze Corporation Gaming machine
KR101246862B1 (ko) * 2004-03-05 2013-03-27 베니텍 리미티드 ＲＮＡｉ 제제의 동시 전달을 위한 다중 프로모터 발현카세트
NZ560936A (en) 2005-02-03 2010-04-30 Benitec Inc RNAI expression constructs

Also Published As

Publication number Publication date
NZ560936A (en) 2010-04-30
EP1844145A2 (fr) 2007-10-17
US20120058555A1 (en) 2012-03-08
US8993530B2 (en) 2015-03-31
EP2172549B1 (fr) 2015-08-26
US20070025969A1 (en) 2007-02-01
IL185315A0 (en) 2008-02-09
CN101180394B (zh) 2013-01-09
US20150197751A1 (en) 2015-07-16
AU2006210443B2 (en) 2011-01-27
CN101180394A (zh) 2008-05-14
WO2006084209A3 (fr) 2007-03-08
EP2172549A3 (fr) 2010-07-07
EP2172549A2 (fr) 2010-04-07
CA2596711A1 (fr) 2006-08-10
US20100028998A1 (en) 2010-02-04
AU2006210443A1 (en) 2006-08-10
CA2596711C (fr) 2015-12-15
US8076471B2 (en) 2011-12-13
WO2006084209A2 (fr) 2006-08-10
DK2172549T3 (en) 2015-11-02
US7803611B2 (en) 2010-09-28

Similar Documents

Publication Publication Date Title
HK1118577A1 (en) Rnai expression constructs rnai
WO2010017562A3 (fr) Cellules souches pluripotentes induites
EP2302034A3 (fr) Procédés améliorés de reprogrammation des cellules somatiques animales
WO2004047747A3 (fr) Compositions et procedes de dedifferentiation cellulaire et de regeneration de tissus
WO2006018836A3 (fr) Constructions d'acides nucleiques et cellules, et methodes faisant appel a ces dernieres pour modifier la fonction electrophysiologique de tissus excitables
GB2472964A (en) Vectors for delivery of light-sensitive proteins and methods of use
NO20090598L (no) 6,9-disubstituerte purinderivater og deres anvendelse for behandling av hud
WO2007022506A3 (fr) Méthodes et préparations pour le traitement d'une maladie neurologique
WO2009120919A3 (fr) Formes galéniques de fénofibrate
IN2009DN07390A (fr)
IL186814A0 (en) Methods, compositions and articles of manufacture for enhancing survivability of cells, tissues, organs and organisms
WO2006133271A3 (fr) Compositions et methodes portant sur une therapie photodynamique ciblee
WO2009007855A3 (fr) Inhibition réversible de l'expression d'un gène huntingtine mutant et endogène de type sauvage par l'arnsi et son application pour le traitement d'une maladie de huntington
UA91895C2 (en) Thiazole compounds and methods of use
WO2007035213A3 (fr) Ongules transgeniques exprimant la ctla4-ig et leurs utilisations
EP2365816A4 (fr) Composition comprenant des cellules souches mésenchymateuses ou une solution de culture de cellules souches mesenchymateuses pour la prevention et le traitement de maladies neurales
WO2008042231A3 (fr) Compositions et méthodes d'évaluation et de traitement de l'insuffisance cardiaque
EP2029754A4 (fr) Expression du gène codant pour les magnétosomes dans des cellules eucaryotes
WO2007064846A3 (fr) Compositions et procedes d'utilisation d'arnsi pour inactiver l'expression genique et ameliorer la transplantation d'organes solides et de cellules
WO2010009478A3 (fr) Compositions et procédés pour traiter des troubles associés à des animaux en surpoids
DK1526840T3 (da) Nanopartikler til DNA administration til et målorgan
WO2006064197A3 (fr) Animaux transgeniques pour evaluer le metabolisme et la toxicite d'un medicament
WO2006093860A3 (fr) Methode et composition pour reparer un tissu cardiaque
WO2009047568A3 (fr) Conservation in vitro de cellules animales vivantes et composés appropriés pour être utilisés dans la conservation de cellules animales vivantes
WO2008099280A3 (fr) Régulation de l'expression de la protéine pi3kb dans les tumeurs

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20170203